Browse All

Current Filters

CLEAR FILTER x

TITLE

Treatment of Amyotrophic Lateral Sclerosis in General and Specialist US Healthcare Settings: Results From a Real-World Survey

Author:Ciepielewska, Malgorzata   DaSilva, Polina   Wright, Jack   Ball, Nathan   Iqbal, Halima   RINGLAND, CIARA   

Session Name:P8: General Neurology: Motor Neuron Disease 1  

Topic:General Neurology  

Program Number:P8.012  

Author Institution:Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Adelphi Real World, Bollington, United Kingdom  

Evolution of the Treatment Landscape for Patients Diagnosed with Amyotrophic Lateral Sclerosis in the United States

Author:Ciepielewska, Malgorzata   Chandak, Aastha   Khachatryan, Artak   lavu, Alekhya   DaSilva, Polina   

Session Name:P9: General Neurology: Motor Neuron Disease 2  

Topic:General Neurology  

Program Number:P9.006  

Author Institution:Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Certara, Randor, PA  

Extension Study MT-1186-A04 Evaluating Oral Edaravone (Radicava ORS®) Continued Efficacy and Safety up to an Additional 48 Weeks in Patients With ALS

Author:Genge, Angela   Rothstein, Jeffrey   De Silva, Shari   Zinman, Lorne   Chum, Marvin   Chio, Adriano   Sobue, Gen   Doyu, Manabu   Selness, Daniel   Todorovic, Vesna   Sasson, Nissim   Takahashi, Fumihiro   Cecic, Michelle   Wamil, Art   Apple, Stephen   

Session Name:P9: General Neurology: Motor Neuron Disease 2  

Topic:General Neurology  

Program Number:P9.007  

Author Institution:Montreal Neurological Institute and Hospital, Montreal, QC, Canada  Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD  Woodland Research Northwest, Rogers, AR  Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada  McMaster University Health Sciences Centre, Hamilton, ON, Canada  Università degli Studi di Torino, Centro Regionale Esperto per la Sclerosi Laterale Amiotrofica (CRESLA), Torino, Italy  Nagoya University Graduate School of Medicine, Aichi Medical University, Nagoya, Japan  Department of Neurology, Aichi Medical University, Nagakute, Japan  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Mitsubishi Tanabe Pharma Europe, Ltd., London, United Kingdom  NStat Solutions, Biostatistical Services, Rehovot, Israel  

Quality of Life with 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): QoL Results from a Phase 3 Randomized, Active-controlled Study

Author:Sarva, Harini   Tagliati, Michele   Poewe, Werner   Stocchi, Fabrizio   Rascol, Olivier   Yardeni, Tami   Lopes, Nelson   Pereira, Jonathan   Espay, Alberto   

Session Name:P11: Movement Disorders: Therapeutics in Study for Parkinson's Disease  

Topic:Movement Disorders  

Program Number:P11.007  

Author Institution:Weill Cornell Medical Center, New York, NY  Cedars-Sinai Medical Center, Movement Disorder Program, Los Angeles, CA  Department of Neurology, Medical University Innsbruck, Innsbruck, Austria  University San Raffaele Roma and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy  University of Toulouse 3, University Hospital of Toulouse, INSERM  Clinical Investigation Center CIC1436 Departments of Neurosciences and Clinical Pharmacology and NS-Park/FCRIN network, Toulouse, France  NeuroDerm Ltd. , Rehovot, Israel  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  James J and Joan A Gardner Center for Parkinson’s disease and Movement, University of Cincinnati, Cincinnati, OH